Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant: Antimicrobial Resistance - EOI

Université Laval

$9,918.00

Tools, formulations, procedures, and strategies to foster continuous innovative improvement and streamline the evaluation and implementation of point-of-care tests for the detection and identification antimicrobial-resistant pathogens

EF 2016-17

Résumé
The molecular diagnostics team led by Professor Michel G. Bergeron created, manufactured and marketed the first FDA- and Health Canada-approved diagnostic tests using the real-time PCR technology to allow timely detection of DNA in hospital laboratories. These laboratory-based tests help fight infections while saving healthcare costs and reducing morbidity and mortality. However, the complexity of these tests limits their use to well-equipped laboratories staffed with skilled technicians. This is why our team has been working on an innovative newer generation of tests performed using a compact portable instrument suitable for point-of-care testing, thus closer to patients and more responsive to healthcare system needs. Our team is already developing rapid molecular tests to detect and identify several of the AMR priority pathogens listed in this funding opportunity. This research proposal will serve to find creative solutions to some of the remaining challenges to demonstrate that this new entirely Canadian point-of-care technology answers the broadest market needs and is most efficient in improving health care delivery to help control costs and suffering by reducing the impact of antibiotic resistant bacteria on our population.
Programme
Operating Grant: Antimicrobial Resistance - EOI
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
349745
Name
Bergeron Michel G
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Special Cases
Projecttitle
Tools, formulations, procedures, and strategies to foster continuous innovative improvement and streamline the evaluation and implementation of point-of-care tests for the detection and identification antimicrobial-resistant pathogens
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$9,918
Cihrequipment2
$0
Programname2
Operating Grant: Antimicrobial Resistance - EOI
Keyworddelim
Antibiotic Resistance; Molecular Diagnostics; Point-Of-Care Rapid Molecular Testing
Abstract
The molecular diagnostics team led by Professor Michel G. Bergeron created, manufactured and marketed the first FDA- and Health Canada-approved diagnostic tests using the real-time PCR technology to allow timely detection of DNA in hospital laboratories. These laboratory-based tests help fight infections while saving healthcare costs and reducing morbidity and mortality. However, the complexity of these tests limits their use to well-equipped laboratories staffed with skilled technicians. This is why our team has been working on an innovative newer generation of tests performed using a compact portable instrument suitable for point-of-care testing, thus closer to patients and more responsive to healthcare system needs. Our team is already developing rapid molecular tests to detect and identify several of the AMR priority pathogens listed in this funding opportunity. This research proposal will serve to find creative solutions to some of the remaining challenges to demonstrate that this new entirely Canadian point-of-care technology answers the broadest market needs and is most efficient in improving health care delivery to help control costs and suffering by reducing the impact of antibiotic resistant bacteria on our population.
Competitiondate
201605
Approvedterm2
0 yr 8 mths
Pinamesdelim
Bergeron, Michel G
Approvedterm
0 an 8 mois
Cihrcontribution2
~ $9,918~ $0~